Connect with us

Buying Biotech Penny Stocks? 3 Trading Tips And 7 To Watch

Are biotech penny stocks worth it? Here’s 3 tips for investing and 7 small-caps to watch
The post Buying Biotech Penny Stocks? 3 Trading Tips And 7 To Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Published

on

How to Find The Best Biotech Penny Stocks to Buy in 2021 

Biotech penny stocks have become some of the most popular stocks to watch in 2021. This began at the start of the pandemic after many leading penny stocks in the biotech industry fell in value substantially. While this made sense given the nature of the pandemic, it was disheartening for all investors. Quickly, however, many leading companies involved in either a treatment or a vaccine began to push up in value. 

This includes non-penny stocks like Johnson & Johnson (NYSE: JNJ), Moderna Inc. (NASDAQ: MRNA), and BioNTech ADR (NASDAQ: BNTX). Additionally, penny stocks like Enzolytics Inc. (OTC: ENZC) and more. Since that time, many investors have switched their focus from Covid-related biotech stocks to other stocks in the biotech industry regardless of their involvement in Covid. Because of this, it’s worth understanding what makes them different from the entire list of penny stocks, and how to trade them. 

[Read More] Hot Penny Stocks to Buy in 2021? Check These 7 Out Right Now

While it can be self-explanatory if you already buy and sell small caps, there are some nuances for every investor to consider. This includes what to look for in a biotech penny stock, current market trends, and understanding what makes them move. So to go further into depth, let’s take a look at three trading tips and seven biotech penny stocks to watch. 

3 Trading Tips For Biotech Penny Stocks Investors

  1. What to Look For in a Biotech Penny Stock 
  2. Current Biotech Market Trends 
  3. Understanding Why Biotech Stocks Move

What to Look for in a Biotech Penny Stock 

When looking for a biotech penny stock to watch, there are a few things to keep track of. The first and arguably the most important is what’s in its pipeline. Does it have any compounds or medical tech devices that are approved? How far are they in the approval process and are any of them commercialized? These are extremely important as they tell how far a company is from profitability or at least a consistent revenue stream. 

The next factor to consider is what its financial situation is. Most biotech companies will not turn any revenue until a product is either fully commercialized or licensed out to another company for production. So you might be wondering how they operate in the meantime? The answer is simple. 

Through either dilutive or non-dilutive financing measures, biotech companies can raise substantial amounts of capital. We often see large share sales, bought-deal offerings, or share offerings that bring in hundreds of millions of dollars. While capital is important to any company, biotech businesses need it in order to keep operations running. And, if we consider how expensive and time-consuming the FDA approval process is, this makes even more sense. So, both of these factors should always be in mind when looking for a biotech stock to watch. 

Current Biotech Market Trends 

Biotech Companies Involved in a Covid Treatment or Cure 

One of the leading market trends over the past year and a half has been biotech penny stocks involved in a Covid treatment or cure. This makes sense given the massive effects of the pandemic on the biotech industry and the stock market as a whole. But, while the first thought may be vaccine-related companies, there are plenty of others working on treatments that are not as well known.

covid biotech stocks

This includes those such as Atossa Therapeutics Inc. (NASDAQ: ATOS), which only just left penny stock territory, as well as many others. Atossa produces a compound known as AT-301, which is an intranasal spray given to those recently diagnosed with SARS-CoV-2. This could be a major breakthrough for early Covid cases, and ATOS stock is only recently getting the attention it deserves. 

[Read More] Top 10 Biotech Penny Stocks to Watch in July 2021

One thing to keep in mind is that companies involved in Covid are highly speculative in relation to any Covid related news. This makes sense and could be quite obvious, but it is something to consider. Of course, there are less volatile Covid-related stocks, but the majority of them tend to trade with at least some degree of correlation to the pandemic. 

Non-Covid-Related Biotech Companies 

This category includes all other biotech companies and has received a great deal of attention as the focus has shifted onto biotech as a whole. As stated earlier, it’s important to keep in mind all of the normal factors we consider when investing in penny stocks. However, with biotech, this can differ greatly. One of the largest ways that we can break this huge category down is by size. 

On one hand, we have the bigger biotech penny stocks. This includes those with several commercialized products, large partnerships and acquisitions, and sizable revenue streams. These companies tend to be quite popular and are always worth watching. 

market trends biotech stocks

But, on the other side, we have less well-known biotech penny stocks. These could be younger companies or those with only one or two products in the pipeline. The small companies can be worth looking into, but they do tend to be highly speculative based on any and all recent news. 

With these, investors should understand what the potential market size for a product is, and how close that compound is to commercialization. Or if not commercialization, at the least, how close it is to progressing through the FDA trials. Whether big or small biotech penny stocks are your thing, there is no doubt that there is a lot of potential in the biotech industry as a whole. It all comes down to knowing where to look. 

7 Biotech Penny Stocks to Watch 

  1. vTv Therapeutics Inc. (NASDAQ: VTVT
  2. Opko Health Inc. (NASDAQ: OPK
  3. Intec Pharma Ltd. (NASDAQ: NTEC
  4. Ocugen Inc. (NASDAQ: OCGN
  5. Citius Pharmaceuticals Inc. (NASDAQ: CTXR
  6. Jaguar Health (NASDAQ: JAGX
  7. Zosano Pharma (NASDAQ: ZSAN

Are Biotech Penny Stocks Worth it or Not?

The short answer to this question is that it all comes down to what type of trader you are. On one end of the spectrum, those who are more risk-averse may want to avoid smaller-name biotech penny stocks. These tend to be highly volatile, and riskier than most.

[Read More] 10 Penny Stocks to Watch as DogeCoin and Bitcoin Push Up

However, if risk is what you’re after then these companies may be right for you. As you can see, understanding what your portfolio goals are, and how to use them to your advantage, will always be your best friend in the stock market. Considering all of this, are biotech penny stocks worth it or not?

The post Buying Biotech Penny Stocks? 3 Trading Tips And 7 To Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Read More

Continue Reading

Government

Low Iron Levels In Blood Could Trigger Long COVID: Study

Low Iron Levels In Blood Could Trigger Long COVID: Study

Authored by Amie Dahnke via The Epoch Times (emphasis ours),

People with inadequate…

Published

on

Low Iron Levels In Blood Could Trigger Long COVID: Study

Authored by Amie Dahnke via The Epoch Times (emphasis ours),

People with inadequate iron levels in their blood due to a COVID-19 infection could be at greater risk of long COVID.

(Shutterstock)

A new study indicates that problems with iron levels in the bloodstream likely trigger chronic inflammation and other conditions associated with the post-COVID phenomenon. The findings, published on March 1 in Nature Immunology, could offer new ways to treat or prevent the condition.

Long COVID Patients Have Low Iron Levels

Researchers at the University of Cambridge pinpointed low iron as a potential link to long-COVID symptoms thanks to a study they initiated shortly after the start of the pandemic. They recruited people who tested positive for the virus to provide blood samples for analysis over a year, which allowed the researchers to look for post-infection changes in the blood. The researchers looked at 214 samples and found that 45 percent of patients reported symptoms of long COVID that lasted between three and 10 months.

In analyzing the blood samples, the research team noticed that people experiencing long COVID had low iron levels, contributing to anemia and low red blood cell production, just two weeks after they were diagnosed with COVID-19. This was true for patients regardless of age, sex, or the initial severity of their infection.

According to one of the study co-authors, the removal of iron from the bloodstream is a natural process and defense mechanism of the body.

But it can jeopardize a person’s recovery.

When the body has an infection, it responds by removing iron from the bloodstream. This protects us from potentially lethal bacteria that capture the iron in the bloodstream and grow rapidly. It’s an evolutionary response that redistributes iron in the body, and the blood plasma becomes an iron desert,” University of Oxford professor Hal Drakesmith said in a press release. “However, if this goes on for a long time, there is less iron for red blood cells, so oxygen is transported less efficiently affecting metabolism and energy production, and for white blood cells, which need iron to work properly. The protective mechanism ends up becoming a problem.”

The research team believes that consistently low iron levels could explain why individuals with long COVID continue to experience fatigue and difficulty exercising. As such, the researchers suggested iron supplementation to help regulate and prevent the often debilitating symptoms associated with long COVID.

It isn’t necessarily the case that individuals don’t have enough iron in their body, it’s just that it’s trapped in the wrong place,” Aimee Hanson, a postdoctoral researcher at the University of Cambridge who worked on the study, said in the press release. “What we need is a way to remobilize the iron and pull it back into the bloodstream, where it becomes more useful to the red blood cells.”

The research team pointed out that iron supplementation isn’t always straightforward. Achieving the right level of iron varies from person to person. Too much iron can cause stomach issues, ranging from constipation, nausea, and abdominal pain to gastritis and gastric lesions.

1 in 5 Still Affected by Long COVID

COVID-19 has affected nearly 40 percent of Americans, with one in five of those still suffering from symptoms of long COVID, according to the U.S. Centers for Disease Control and Prevention (CDC). Long COVID is marked by health issues that continue at least four weeks after an individual was initially diagnosed with COVID-19. Symptoms can last for days, weeks, months, or years and may include fatigue, cough or chest pain, headache, brain fog, depression or anxiety, digestive issues, and joint or muscle pain.

Tyler Durden Sat, 03/09/2024 - 12:50

Read More

Continue Reading

Uncategorized

February Employment Situation

By Paul Gomme and Peter Rupert The establishment data from the BLS showed a 275,000 increase in payroll employment for February, outpacing the 230,000…

Published

on

By Paul Gomme and Peter Rupert

The establishment data from the BLS showed a 275,000 increase in payroll employment for February, outpacing the 230,000 average over the previous 12 months. The payroll data for January and December were revised down by a total of 167,000. The private sector added 223,000 new jobs, the largest gain since May of last year.

Temporary help services employment continues a steep decline after a sharp post-pandemic rise.

Average hours of work increased from 34.2 to 34.3. The increase, along with the 223,000 private employment increase led to a hefty increase in total hours of 5.6% at an annualized rate, also the largest increase since May of last year.

The establishment report, once again, beat “expectations;” the WSJ survey of economists was 198,000. Other than the downward revisions, mentioned above, another bit of negative news was a smallish increase in wage growth, from $34.52 to $34.57.

The household survey shows that the labor force increased 150,000, a drop in employment of 184,000 and an increase in the number of unemployed persons of 334,000. The labor force participation rate held steady at 62.5, the employment to population ratio decreased from 60.2 to 60.1 and the unemployment rate increased from 3.66 to 3.86. Remember that the unemployment rate is the number of unemployed relative to the labor force (the number employed plus the number unemployed). Consequently, the unemployment rate can go up if the number of unemployed rises holding fixed the labor force, or if the labor force shrinks holding the number unemployed unchanged. An increase in the unemployment rate is not necessarily a bad thing: it may reflect a strong labor market drawing “marginally attached” individuals from outside the labor force. Indeed, there was a 96,000 decline in those workers.

Earlier in the week, the BLS announced JOLTS (Job Openings and Labor Turnover Survey) data for January. There isn’t much to report here as the job openings changed little at 8.9 million, the number of hires and total separations were little changed at 5.7 million and 5.3 million, respectively.

As has been the case for the last couple of years, the number of job openings remains higher than the number of unemployed persons.

Also earlier in the week the BLS announced that productivity increased 3.2% in the 4th quarter with output rising 3.5% and hours of work rising 0.3%.

The bottom line is that the labor market continues its surprisingly (to some) strong performance, once again proving stronger than many had expected. This strength makes it difficult to justify any interest rate cuts soon, particularly given the recent inflation spike.

Read More

Continue Reading

Spread & Containment

Another beloved brewery files Chapter 11 bankruptcy

The beer industry has been devastated by covid, changing tastes, and maybe fallout from the Bud Light scandal.

Published

on

Before the covid pandemic, craft beer was having a moment. Most cities had multiple breweries and taprooms with some having so many that people put together the brewery version of a pub crawl.

It was a period where beer snobbery ruled the day and it was not uncommon to hear bar patrons discuss the makeup of the beer the beer they were drinking. This boom period always seemed destined for failure, or at least a retraction as many markets seemed to have more craft breweries than they could support.

Related: Fast-food chain closes more stores after Chapter 11 bankruptcy

The pandemic, however, hastened that downfall. Many of these local and regional craft breweries counted on in-person sales to drive their business. 

And while many had local and regional distribution, selling through a third party comes with much lower margins. Direct sales drove their business and the pandemic forced many breweries to shut down their taprooms during the period where social distancing rules were in effect.

During those months the breweries still had rent and employees to pay while little money was coming in. That led to a number of popular beermakers including San Francisco's nationally-known Anchor Brewing as well as many regional favorites including Chicago’s Metropolitan Brewing, New Jersey’s Flying Fish, Denver’s Joyride Brewing, Tampa’s Zydeco Brew Werks, and Cleveland’s Terrestrial Brewing filing bankruptcy.

Some of these brands hope to survive, but others, including Anchor Brewing, fell into Chapter 7 liquidation. Now, another domino has fallen as a popular regional brewery has filed for Chapter 11 bankruptcy protection.

Overall beer sales have fallen.

Image source: Shutterstock

Covid is not the only reason for brewery bankruptcies

While covid deserves some of the blame for brewery failures, it's not the only reason why so many have filed for bankruptcy protection. Overall beer sales have fallen driven by younger people embracing non-alcoholic cocktails, and the rise in popularity of non-beer alcoholic offerings,

Beer sales have fallen to their lowest levels since 1999 and some industry analysts

"Sales declined by more than 5% in the first nine months of the year, dragged down not only by the backlash and boycotts against Anheuser-Busch-owned Bud Light but the changing habits of younger drinkers," according to data from Beer Marketer’s Insights published by the New York Post.

Bud Light parent Anheuser Busch InBev (BUD) faced massive boycotts after it partnered with transgender social media influencer Dylan Mulvaney. It was a very small partnership but it led to a right-wing backlash spurred on by Kid Rock, who posted a video on social media where he chastised the company before shooting up cases of Bud Light with an automatic weapon.

Another brewery files Chapter 11 bankruptcy

Gizmo Brew Works, which does business under the name Roth Brewing Company LLC, filed for Chapter 11 bankruptcy protection on March 8. In its filing, the company checked the box that indicates that its debts are less than $7.5 million and it chooses to proceed under Subchapter V of Chapter 11. 

"Both small business and subchapter V cases are treated differently than a traditional chapter 11 case primarily due to accelerated deadlines and the speed with which the plan is confirmed," USCourts.gov explained. 

Roth Brewing/Gizmo Brew Works shared that it has 50-99 creditors and assets $100,000 and $500,000. The filing noted that the company does expect to have funds available for unsecured creditors. 

The popular brewery operates three taprooms and sells its beer to go at those locations.

"Join us at Gizmo Brew Works Craft Brewery and Taprooms located in Raleigh, Durham, and Chapel Hill, North Carolina. Find us for entertainment, live music, food trucks, beer specials, and most importantly, great-tasting craft beer by Gizmo Brew Works," the company shared on its website.

The company estimates that it has between $1 and $10 million in liabilities (a broad range as the bankruptcy form does not provide a space to be more specific).

Gizmo Brew Works/Roth Brewing did not share a reorganization or funding plan in its bankruptcy filing. An email request for comment sent through the company's contact page was not immediately returned.

 

Read More

Continue Reading

Trending